Ventas (VTR)
(Delayed Data from NYSE)
$64.45 USD
+1.23 (1.95%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $64.43 -0.02 (-0.03%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.45 USD
+1.23 (1.95%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $64.43 -0.02 (-0.03%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Zacks News
Ventas (VTR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While higher supply of senior housing assets may impede Ventas' (VTR) Q4 performance, the company's solid medical office building (MOB) portfolio remains a positive.
Digital Realty (DLR) Q4 FFO Tops Estimates, Revenues Up Y/Y
by Zacks Equity Research
Digital Realty Trust's (DLR) Q4 results highlight decent demand for data-center facilities, encouraging the company to reaffirm its core FFO projections for the current year.
Alexandria (ARE) Q4 FFO & Revenues Miss Estimates, Up Y/Y
by Zacks Equity Research
Alexandria Real Estate Equities' (ARE) Q4 results highlight increase in rental rate. However, expenses tied to rental operations and interests were higher in the quarter.
HT vs. VTR: Which Stock Is the Better Value Option?
by Zacks Equity Research
HT vs. VTR: Which Stock Is the Better Value Option?
Why Trending Outpatient Care is a Boon for Healthcare REITs
by Devyani Chamria
Amid shift of care to low-cost setting, medical office buildings (MOBs) and outpatient facilities have been creating opportunities for healthcare REITs to park their money.
HPT or VTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HPT vs. VTR: Which Stock Is the Better Value Option?
Why Is Ventas (VTR) Up 8% Since Last Earnings Report?
by Zacks Equity Research
Ventas (VTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is it Wise to Hold Ventas (VTR) Stock in Your Portfolio Now?
by Zacks Equity Research
Ventas (VTR) is expected to grow on the back of accretive investments in its medical office and life science real estate portfolio. Yet, escalating supply of senior housing assets is a concern.
Lamar Advertising (LAMR) Q3 AFFO Tops, Revenues Miss Estimates
by Zacks Equity Research
Lamar Advertising's (LAMR) revenues miss the Zacks Consensus Estimate in Q3. Nonetheless, the bottom line witnesses year-over-year growth.
CORR or VTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CORR vs. VTR: Which Stock Is the Better Value Option?
W. P. Carey Buys Automotive Dealership Portfolio for $33M
by Zacks Equity Research
W. P. Carey (WPC) expands in the Netherlands with the acquisition of a portfolio of four automotive retail and service sites that is leased to Van Mossel for 17 years.
Outfront Media (OUT) Beats Q3 FFO and Revenue Estimates
by Zacks Equity Research
Outfront Media's (OUT) third-quarter 2018 FFO and revenues beat estimates. While billboard revenues boosted results, escalating operating expenses remains a drag.
Ventas' (VTR) Q3 FFO Surpasses Estimates, Revenues Up Y/Y
by Zacks Equity Research
Ventas' (VTR) third-quarter results highlight strength in the company's triple net leased and office portfolio.
Ventas (VTR) Tops Q3 FFO and Revenue Estimates
by Zacks Equity Research
Ventas (VTR) delivered FFO and revenue surprises of 2.06% and 3.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Key Factors to Impact Ventas' (VTR) Earnings This Season
by Zacks Equity Research
Higher interest rates may impede Ventas' (VTR) Q3 bottom line. Nonetheless, a strong senior housing portfolio remains the silver lining.
HT or VTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HT vs. VTR: Which Stock Is the Better Value Option?
Equity Residential to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Equity Residential's (EQR) Q3 performance is likely to be driven by strong rental housing demand. However, higher supply is likely to curb growth tempo.
Crown Castle (CCI) to Post Q3 Earnings: What Lies Ahead?
by Zacks Equity Research
Crown Castle International's (CCI) Q3 top-line growth will likely be hindered by rapid adoption of the Voice over WiFi network by mobile handset manufacturers and wireless carriers.
SL Green (SLG) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
SL Green Realty (SLG) will likely gain from its portfolio-repositioning and asset disposition efforts in Q3. Yet, fall in rental revenues may persist in the near term.
Key Factors to Impact Prologis' (PLD) Earnings This Season
by Zacks Equity Research
Prologis' (PLD) Q3 results likely to reflect healthy fundamentals of the industrial real estate market backed by an improving economy and strengthening e-commerce market.
Here's Why You Should Hold Ventas in Your Portfolio Now
by Zacks Equity Research
While a diversified portfolio insulates Ventas' (VTR) performance from any unfavorable market swings, elevated supply of senior housing assets could impact its pricing power in the near future.
Ventas Enhances New York Portfolio With Battery Park Buyout
by Zacks Equity Research
Amid stiff competition with healthcare operators, Ventas (VTR) cracks an attractive deal to acquire Battery Park from Brookdale for around $194 million.
HT or VTR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HT vs. VTR: Which Stock Is the Better Value Option?
Will Rising Healthcare Spending Aid HCP This Earnings Season?
by Zacks Equity Research
HCP Q2 results likely to reflect benefit from shedding of Brookdale assets. However, rising interest rates remains a concern.
Ventas' (VTR) Q2 FFO & Revenues Trump Estimates, NOI Up
by Zacks Equity Research
Ventas' (VTR) Q2 results highlight the company's efforts to diversify its business into university-based life-science projects.